Tim Mayleben

Tim M.
Mayleben is the founder of Esperance BioVentures LLC, founded in 1998, serving as Managing Director since 2011.
Mr. Mayleben is currently the Director at Wolverine Venture Fund.
Former positions include President, Chief Executive Officer & Director at Esperion Therapeutics, Inc. from 2012 to 2021, Non-Executive Chairman at Kaleo, Inc., Director at Aksys Ltd., Director at Vericel Corp.
from 2012 to 2013, Director at Rubicon Genomics, Inc., President, Chief Operating Officer & Director at NightHawk Radiology Holdings, Inc. from 2005 to 2008, Director at Solulink, Inc., Director at Lycera Corp., Independent Director at Loxo Oncology, Inc. from 2015 to 2019, Independent Director at Landos Biopharma, Inc. from 2022 to 2024, Lead Independent Director at Marinus Pharmaceuticals, Inc. from 2022 to 2025, Chief Operating & Financial Officer at Esperion Therapeutics, Inc. from 1998 to 2004, Principal at Applied Intelligent Systems, Inc., Executive Officer at Transom Technologies, Inc., and Advisory Board Member at Michigan Ross Zell Lurie Institute.
Education includes an undergraduate degree from Stephen M.
Ross School of Business, conferred in 1984, and an MBA from Kellogg School of Management, conferred in 1997.